Form 4: MaxCyte Director Richard Douglas Receives Annual Equity Grant

MaxCyte, Inc. Director Richard Douglas was granted 29,210 restricted stock units and 50,790 stock options as part of his annual compensation, as disclosed in a recent SEC Form 4 filing.

Summary

• Richard Douglas, a Director of MaxCyte, Inc. (MXCT), reported new equity grants.
• On June 18, 2025, he acquired 29,210 Restricted Stock Units (RSUs) at a price of $0.00 per share. Each RSU represents a contingent right to receive one share of MaxCyte's Common Stock.
• Concurrently, he acquired 50,790 stock options with an exercise price of $2.11 per share. These options expire on June 17, 2035.
• These grants are part of the Issuer's Equity Grant Policy for non-employee directors.
• The shares underlying the RSU grant will vest on June 18, 2026, contingent upon Mr. Douglas's continuous service.
• Following these transactions, Mr. Douglas beneficially owns 150,577 shares of Common Stock and 50,790 stock options.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing detailing an annual equity grant to a director. It is a factual disclosure of a standard compensation event and does not contain information that would significantly alter the company's outlook or financial position, thus indicating a neutral sentiment.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with long-term shareholder value.
• The grants are part of a standard, pre-defined equity grant policy for non-employee directors, indicating a structured compensation approach.

Risks

• The vesting of the restricted stock units is subject to the reporting person's continuous service, meaning the shares could be forfeited if service ceases before the vesting date.
• The value of the stock options is dependent on the future stock price of MaxCyte, Inc. exceeding the exercise price of $2.11.

Future Outlook

The vesting of the restricted stock units on June 18, 2026, is contingent on the director's continuous service, indicating a future milestone for the equity compensation.

Industry Context

This filing represents a routine equity compensation grant to a non-employee director, a common practice across publicly traded companies to align director incentives with shareholder interests. It does not provide broader industry trends or competitive insights.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to a director (Richard Douglas) by MaxCyte, Inc. constitutes a related party transaction, as it involves compensation from the company to a member of its board. This is a standard and disclosed form of related party compensation.

Stakeholder Impact

• Shareholders: The grant of equity aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term stock value. It also represents dilution from new share issuance upon RSU vesting and option exercise.

Next Steps

• The Restricted Stock Units are scheduled to vest on June 18, 2026, provided the director maintains continuous service.

Key Dates

Keywords

MaxCyte, MXCT, SEC Form 4, Richard Douglas, Director Compensation, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, Beneficial Ownership